Anacor Pharma (ANAC) Posts Wider Q3 Loss

Anacor Pharma (NASDAQ: ANAC) reported Q3 EPS of ($0.74), $0.08 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $4 million versus the consensus estimate of $3.67 million.

Cash, cash equivalents and investments totaled $148.9 million at September 30, 2014, compared to $166.8 million at December 31, 2013. Investment balances at September 30, 2014 and December 31, 2013 include short-term and long-term investments, as well as $3.4 million and $4.6 million of restricted investments, respectively.

For earnings history and earnings-related data on Anacor Pharma (ANAC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Reading (RDI) Tops Q2 EPS by 4c